Hemophagocytic Lymphohistiocytosis: A Review

Sirisha Rani Siddaiahgari, Shirali Agarwal, Pallavi Madukuri and Latha Subramanyam Moodahadu
Rainbow Children’s Hospital, Hyderabad, India

Corresponding author: Sirisha Rani Siddaiahgari, Department of Hemato oncology, Rainbow Children’s Hospital, 22, Road No. 4, (Old Road No. 10), Karvy Lanes, Banjara Hills, Hyderabad, Telangana, India, Tel: 09959885558; E-mail: lokisiri@gmail.com

Received date: Jun 15, 2016, Accepted date: Jul 30, 2016, Publication date: Aug 03, 2016

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a disorder characterised by immune dysregulation. Though it was underdiagnosed earlier now it is increasingly being diagnosed across the world with better awareness among physicians. “Hypercytokinemia” which is the hallmark of HLH can result in end organ damage and even death in some cases if there is delay in diagnosis. It has a wide array of presentation but commonly presents as fever with organomegaly and bicytopenia. A vast majority of cases are acquired due to secondary causes but primary HLH is also not uncommon which also intern gets triggered by infection as suggested by recent studies. Laboratory parameters like Ferritin, triglycerides and fibrinogen along with bicytopenia/pancytopenia aid in further confirmation of this diagnosis. Bone marrow may or may not show evidence of HLH. Hence absence of involvement should not exclude the diagnosis of HLH. Newer modalities like flow cytometry and genetic analysis have contributed for widespread recognition of its pathogenesis and etiology. Like various other emergencies, timely diagnosis remains one of the key stones of its management. Management is largely based on HLH-2004 protocol for secondary cases and almost all cases of primary HLH require Hematopoetic Stem Cell transplantation after initial treatment with HLH 2004 protocol. Recent advances have been made in exploring other modalities of treatment like immunomodulatory agents and monoclonal antibodies (ATG, Alemtuzumab, IFN-γ) for resistant/refractory cases to achieve desirable outcomes. Our article aims to summarize the new advances in the diagnosis and management of HLH and also gives comprehensive review of the pathophysiology, clinical observations and modern laboratory methods for HLH diagnosis. Early and prompt recognition remains the gold standard to decrease the mortality related to this condition.

Keywords: Hemophagocytic lymphohistiocytosis diagnostic criteria and management; Flow cytometry role in diagnosis; Newer modalities of HLH treatment

Introduction

Hemophagocytic Lymphohistiocytosis (HLH), a rare phenomenon of immune dysregulation, primarily recognized in pediatric patients, is relatively under diagnosed owing to varied manifestations and lack of awareness among medical fraternity. It can either be sporadic or familial, generally being precipitated by a triggering event such as infection or malignancy. It was first reported in 1952 by Farquhar and Claireaux. Chemotherapy has proved very effective in controlling and curing HLH apart from prolonging survival.

It affects both genders though slight male predisposition is seen in adolescents [1,2]. Incidence is reported to be as high as 1 in 3000 in pediatric hospital admissions. Positive family history such as parental consanguinity and death of a sibling can be a leading clue owing to autosomal recessive nature of inheritance [3,4].

Early diagnosis of this rare but fatal condition is crucial as the spectrum of clinical presentation varies from simple fever to severe inflammation “i.e.,” organomegaly, bicytopenias and occasionally end organ damage, mimicking frequently encountered pathological entities. This increases the chances of misdiagnosing the condition, but associated cutaneous changes in HLH prompt the physician to suspect.

HLH is of clinical interest to us because of its ability to mimic any symptom. In developed countries where they have lesser number of infections, diagnosis can be made without much difficulty, whereas in developing countries like India, where infections are still a major concern to the physicians, making an accurate diagnosis, is crucial.

In this review we discuss various aspects of HLH which includes classification, pathophysiology, clinical features, investigations, standard treatment, proposed treatment modalities, and future scope. Through this review we intend to create and increase the awareness among medical fraternity particularly pediatricians.

Classification

HLH is classified based on its aetiology [5] (Figure 1). Distinguishing primary from secondary is crucial as management is different in each type. Primary HLH is seen in pediatric age group while secondary is common among adults and elderly. The genetic forms of HLH can be divided into Familial HLH (FHLH) associated with immunodeficiency syndromes and without any association with syndromes. Family history may not be elicitable owing to recessive nature of the disease. Most of the genes implicated are the ones coding components of perforin gene accounting for 50% of all FHL cases [6,7]. There exist other genetic defects in regulating the packaging, transport, or release of cytotoxic granules. Table 1 shows characteristics of mutations observed at FLH loci [1,8,9] and its genetic defect.

The immunodeficiency syndromes to be associated with HLH (Table 2) are Chédiak-Higashi syndrome (CHS-1), Griscelli syndrome type 2(GS-2) [10,11], Hermansky-Pudlak syndrome type 2, and X-linked proliferative syndrome (XLP-1) also called Duncan disease, characterized by an abnormal response to Epstein Barr virus infection (Table 2).
Most common form is secondary HLH and many of these cases occur following infections. Clinically HLH can also be seen in association with rheumatological conditions such as Juvenile Idiopathic arthritis or systemic lupus erythematosus (SLE). New terminology ‘Macrophage Activation Syndrome’ (MAS) has been proposed for this type of HLH. Rheumatologic disorders causing MAS are systemic onset juvenile idiopathic arthritis, SLE, polyarteritis nodosum, mixed connective tissue disease, sarcoidosis, systemic Sclerosis, and Sjögren’s syndrome and Antiphospholipid syndrome.

Emergence of newer informations, updates and findings have necessitated the need of revisions in the classification of HLH. Working group of the Histiocyte Society has considered only three types of cells i.e., Langerhans cells, non-Langerhans related, and malignant histiocytosis in their classification. Emile et al. [12] have suggested a revision to the existing classification by including two more cell types. They have suggested Langerhans-related, cutaneous and mucocutaneous, malignant histiocytoses Rosai-Dorfman disease hemophagocytic lymphohistiocytosis and macrophage activation syndrome in the proposed classification.

<table>
<thead>
<tr>
<th>FHL subclass</th>
<th>Chromosome</th>
<th>Gene</th>
<th>Gene function</th>
<th>Protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>FHL-1</td>
<td>9q21.3-q22</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>FHL-2</td>
<td>10q21-22</td>
<td>PFR1</td>
<td>Induction of apoptosis</td>
<td>Perforin</td>
</tr>
<tr>
<td>FHL-3</td>
<td>17q25</td>
<td>UNC13D</td>
<td>Vesicle priming</td>
<td>Munc13-4</td>
</tr>
<tr>
<td>FHL-4</td>
<td>6q24</td>
<td>STX11</td>
<td>Vesicle transport</td>
<td>Syntaxin11</td>
</tr>
<tr>
<td>FHL-5</td>
<td>19p13.2-3</td>
<td>STXBP2 (UNC18B)</td>
<td>Vesicle transport</td>
<td>Munc18-2</td>
</tr>
</tbody>
</table>

Table 1: Mutations at FLH loci and its genetic defect.

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Chromosome</th>
<th>Gene</th>
<th>Gene function</th>
<th>Protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHS-1</td>
<td>1q42.1-q42.2</td>
<td>LYST</td>
<td>Vesicle transport</td>
<td>Lyst</td>
</tr>
<tr>
<td>GS-2</td>
<td>15q21</td>
<td>RAB27A</td>
<td>Vesicle transport</td>
<td>Rab27a</td>
</tr>
<tr>
<td>XLP-1</td>
<td>Xq25</td>
<td>SH2D1A</td>
<td>Signal transduction and activation of lymphocytes</td>
<td>SAP</td>
</tr>
<tr>
<td>XLP-2</td>
<td>Xq25</td>
<td>BIRC4</td>
<td>Various signalling pathways</td>
<td>XIAP</td>
</tr>
</tbody>
</table>

Table 2: Mutations associated with various Syndromes with HLH.

Pathophysiology

HLH is a syndrome of extensive inflammation due to abnormal activation of immune cells, which results in lack of normal down regulation of activated macrophages and lymphocytes which then cause tissue destruction [13]. In HLH the impaired cytotoxic function of natural killer (NK) cells and cytotoxic lymphocytes (CTLs) results in faulty elimination of macrophages, leading to uncontrolled activation [14-20]. Lysis of target cells is a cascade, where in there is formation of an immunological synapse creating a pore in macrophages following which there is an exchange of cytolytic granules containing granzyme and other proteins which eventually causing apoptosis of the cells (Figure 2).

The genetic defects occurring at various levels of this cascade in HLH, hinders the normal apoptosis causing excessive activation of macrophages and hypercytokinemia (Figure 2) [12]. These cytokines are interferon gamma, tumor necrosis factor alpha (TNF-α), interleukins (IL) such as IL-6, IL-10, and IL-12; and the soluble IL-2 receptor (CD25). Elevated IL-16 is important for TH1-type response that recruits macrophages and other cells causing HLH [21-23]. Another cause of HLH is activation of Toll-like receptor (TLR) [24] which are non-antigen-specific receptors on the surface of NK cells that can be activated by components of bacteria, fungi, viruses, or mycoplasma (Figure 2). In MAS, genes causing TLR/interleukin 1 receptor (IL-1R) signalling are upregulated [25] resulting in hemophagocytosis.

The precipitating factor is infection in most cases triggering an acute episode and leading to immune homeostasis alteration. The most commonly implicated organisms are viruses “i.e.,” Epstein-Barr virus, cytomegalovirus, parvovirus, herpes simplex virus, varicella-zoster
virus, HIV etc.), bacteria (Brucella, gram negative bacteria, tuberculosis), parasites (Leishmaniasis, Malaria) and fungi [26,27]. Positive association between HLH and malignancies like leukemias, lymphomas and solid tumors have been well documented [28]. Genetic understanding is essential for the physician to determine likelihood of recurrence, the need for hematopoietic cell transplant, and the risk of HLH in family members.

Positive association between HLH and malignancies like leukemias, lymphomas and solid tumors have been well documented [28]. Genetic understanding is essential for the physician to determine likelihood of recurrence, the need for hematopoietic cell transplant, and the risk of HLH in family members. Presenting with features of respiratory problems like ARDS, hypotension and renal dysfunction even requiring dialysis, syndrome specific features like albinism, photosensitivity and silvery grey hair like in chediak higashi/griscelli syndrome are not uncommon.

Despite well recognized characteristic symptoms, diagnosis is difficult as the clinical presentation may mimic many other clinical conditions [30]. Investigations aid in arriving at a diagnosis of HLH; hence, it is essential to follow a thorough work up.

Clinical Features

Clinical features of HLH have wide spectrum, thus arriving at accurate diagnosis is challenging. The presenting features is generally a febrile illness associated with multiple organs involvement “i.e.,” fever, rash (erythoderma), hepatosplenomegaly, lymphadenopathy, edema, bleeding manifestations, icterus, liver dysfunction and neurological symptoms such as seizures, altered mentation, ataxia and posterior reversible encephalopathy syndrome (PRES) like picture especially in case of FHLH.

Magnetic resonance imaging (MRI) of the brain in these patients can show hypodense areas. Almost around half of FHLH patients have CNS involvement [29]. If central nervous system (CNS) involvement is present there is a manifold increase in the risk for mortality and neurologic sequelae [4,30,31].

Presenting with features of respiratory problems like ARDS, hypotension and renal dysfunction even requiring dialysis, syndrome specific features like albinism, photosensitivity and silvery grey hair like in chediak higashi/griscelli syndrome are not uncommon.

Despite well recognized characteristic symptoms, diagnosis is difficult as the clinical presentation may mimic many other clinical conditions [30]. Investigations aid in arriving at a diagnosis of HLH; hence, it is essential to follow a thorough work up.
Liver biopsy

Lymphocytic infiltrates is seen frequently and chronic persistent hepatitis with periportal lymphocytic infiltration can be seen in severe cases.

Cerebrospinal fluid (CSF) analysis

Cellular pleocytosis, elevated proteins and hemophagocytosis can be detected on CSF analysis. As a part of specialized testing several investigations specially to elicit genetic causes must be performed [30,31].

Immunologic profile

Underlying disease pathology causes hypercytokinemia. Thus, identifying these cytokines, along with NK cells CTls in immunologic profile has been proved useful in diagnosis [30].

Elevated Soluble IL-2 receptor alpha (sCD25) found to correlate with disease activity [36]. NK cell function/degranulation (e.g. by flow cytometry for surface expression of the lysosomal-associated membrane protein1 [LAMP-1, also called CD107alpha]) are found to be decreased in these patients.

Low CD107a on peripheral blood mononuclear cells is a marker for UNC13D, STX11, STXBP2, and RAB27A mutations which can be detected through phyo hemagglutination or antiCD3 stimulation by flow cytometry.

Detection of perforin expression on cytotoxic T cells by flow cytometry is one of the rapid diagnostic tool to detect homozygous mutations, but with limitations of variable protein expression (especially in heterozygous cases).

Flow cytometry for cell surface expression of SAP and XIAP/SH2D1A (decreased) can be used in males. Increased levels of the hemoglobin-haptoglobin scavenger receptor (sCD163), Immunoglobulin levels (e.g. IgG, IgA, IgM) and lymphocyte subsets are also useful investigation in the diagnosis of HLH [13,27,37-39].

Genetics and HLA testing

A genetic analysis is not practical in all cases in developing countries such as India. However, it is mandatory in children with CNS involvement, relapsing/refractory disease, disease with significant multiorgan involvement and children born to consanguineous parents/with positive family history. Viral titres, body fluids cultures should be performed.

List of parameters to be tested are provided in Tables 1 and 2.

Clinical Investigations

- Echocardiogram and Chest X ray should be done wherever relevant to rule out cardiovascular and respiratory aetiology and involvement.
- Imaging of the CNS may show parameningeal infiltrations, subdural effusion and necrosis.
- Progressively increasing transaminases, bilirubin, coagulopathy, ferritin, and sCD25 levels as well as deteriorating respiratory status are considered poor prognostic signs.

HLH 2004 Diagnostic Criteria

Currently, HLH 2004 diagnostic criteria are followed worldwide [38]. However, in 2009, a new proposal was put forth by HLH society [39]. Diagnostic criteria as described by the existing and proposed are tabulated in Table 3.

<table>
<thead>
<tr>
<th>HLH 2004 diagnostic criteria</th>
<th>Proposed diagnostic criteria 2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Molecular diagnosis consistent with HLH. Pathologic mutations of PRF1, UNC13D or STX11 are identified.</td>
<td>a. Molecular diagnosis consistent with HLH or X-linked lymphoproliferative syndrome (XLP).</td>
</tr>
<tr>
<td>OR</td>
<td>OR</td>
</tr>
<tr>
<td>b. Fulfilment of five of eight of the following criteria</td>
<td>b. Fulfilment of at least three of four following criteria</td>
</tr>
<tr>
<td>• Fever</td>
<td>• Fever</td>
</tr>
<tr>
<td>• Spleenomegaly</td>
<td>• Spleenomegaly</td>
</tr>
<tr>
<td>• Cytopenias (affecting at least two of three lineages in the peripheral blood)</td>
<td>• Cytopenias (minimum 2 cell lines reduced)</td>
</tr>
<tr>
<td>• Hemoglobin &lt;9 g/100 ml (in infants &lt;4 weeks: hemoglobin &lt;10 g/100 ml)</td>
<td>• Hepatitits</td>
</tr>
</tbody>
</table>
- Platelets <100 ×10^3/μl
- Neutrophils <1×10^3/μl
- Hypertriglyceridemia (fasting, ≥265 mg/100 ml) and/or hypofibrinogenemia (≤150 mg/100 ml)
- Hemophagocytosis in BM, spleen or lymph nodes
- Low or absent NK cell activity
- Ferritin ≥ 500 ng/ml
- Soluble CD25 (soluble IL-2 receptor) >2400 U/ml (or per local reference laboratory)

Table 3: HLH 2004 diagnostic criteria and HLH proposed diagnostic criteria 2009.

**Treatment**

Success rates have been found to be dependent on early/timely diagnosis and prompt initiation of treatment. Treatment should be directed at controlling the triggering infection, arresting the proliferation and further activation of T-cells. Inhibiting the production of cytokines that promote inflammatory process will prevent further activation of inflammatory mediators which in turn will control or stop the further damage [40].

Treatment has been classified as supportive and specific therapy.

**Supportive therapy**

Supportive therapy aims at addressing the infection, source of infection, replacement of blood volume, and in severe cases cardio-respiratory support. Broad-spectrum antibiotics, as per culture report and clinical need are to be administered either orally or parenterally based on severity of the infection [41]. Prophylactic therapy with cotrimoxazole, oral antimycotic agents i.e., fluconazole and antiviral therapy are to be considered in patients with evidence of viral infection.

Administration of Intravenous (IV) immunoglobulin (0.5 g/kg) once every 4 weeks is advised during the initial phase and as per need in continuation therapy. Rituximab is to be considered for those with Ebstein Bar virus infection triggered HLH. Few patients require blood volume replacement particularly those with HLH induced bleeding, clotting factor derangements. Transfusion of blood products, packed red blood cells, platelets, fresh frozen plasma, cryoprecipitate, and occasionally activated factor VII is followed. Cardio-respiratory support, dialysis for renal failure patients may be required in few critically ill children.

**Specific management**

Dexamethasone alone controls the disease significantly in many secondary HLH. However, additional medications may be required in severe HLH whether it is secondary/familial; in such cases, etoposide, Cyclosporine are administered in the treatment along with dexamethasone and intrathecal methotrexate therapy is considered in case of CNS involvement (Table 4).

<table>
<thead>
<tr>
<th>SI No</th>
<th>Drug</th>
<th>Dose and Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Etoposide</td>
<td>150 mg/m², Intravenous, twice a week for week 1-2; once a week for week 3-6</td>
</tr>
<tr>
<td>2</td>
<td>Dexamethasone</td>
<td>10 mg/m²/day for initial 2 weeks, 5 mg/m²/day during week 3-4, 5-2.5 mg/m²/day week 4-6, 1.25 mg/m²/day week 7-8</td>
</tr>
<tr>
<td>3</td>
<td>Cyclosporin A*</td>
<td>Initiate 6 mg/kg daily (2 divided doses) if kidney function is normal. Aim is to achieve trough levels around 200 microgram/L.</td>
</tr>
<tr>
<td>4</td>
<td>Methotrexate-Intrathecal</td>
<td>6 mg for children aged 1 yr 8 mg for children aged 1-2 yrs 10 mg for children aged 2-3 yrs, 12 mg for children aged 3yrs</td>
</tr>
<tr>
<td></td>
<td>Prednisolone-Intrathecal</td>
<td>4 mg for children aged 1 yr 6 mg for children aged 1-2 yrs, 8 mg for children aged 2-3 yrs, 10 mg for children aged 3yrs</td>
</tr>
</tbody>
</table>

**Maintenance Therapy**
When methotrexate and Prednisolone are administered intrathecally, evaluation of CSF to be done at the time of diagnosis and after 2 weeks. If there is clinical evidence of progressive neurological symptoms or abnormal CSF (cells/protein), additional CNS-therapy is initiated with 4 weekly intrathecal injections.

CNS Involvement diagnosed by CSF spread or imaging findings can prove detrimental owing to long term deficits, neurological complications and requires aggressive treatment with weekly injections of intrathecal methotrexate and Hydrocortisone. In addition, HLH chemotherapy to be administered until no abnormality is detected in CSF and symptoms disappear. Dexamethasone helps in reduction of CNS involvement partly by penetrating the blood brain barrier.

Involvement of CNS is predominantly suggestive of a genetic etiology and risk of significant long term morbidity is high. It has been advised to consider Hematopoietic stem cell transplant for such patients.

**Continuation therapy**

Initial therapy is continued with an aim to keep the disease inactive (week 9-40). It is advisable to continue the therapy in Non-familial diseases/no genetic evidence of HLH, only if the disease is active after initial therapy.

In case of genetically proven HLH after initial therapy once disease is under control, HSCT is mandatory.

**Stem cell transplantation**

In primary HLH, which is genetically proven, allogeneic Stem Cell Transplant (SCT) is the only curative therapy. For stem cell transplantation, an HLA-identical donor is preferable. The risk of a sibling carrying the disease must be considered; carrier state is less likely if older sibling is considered as donor, but this age criteria cannot be used as an indicator for being non-affected. In the absence of a genetic marker (as perforin/hMunc), NK-cell activity can be considered as a surrogate marker of immune dysfunction. In situations of non-availability of an HLA-identical relative, SCT with a matched unrelated donor is recommended. If there is no matched donor available, a mismatched donor (including a haploidentical family donor) or cord blood is suggested, as decided by the physician. The therapeutic outcomes with mismatched donors are improving in the recent past. SCT to be considered in primary HLH once the disease is under control after the initial therapy [42].

**New approaches in therapy**

Despite all aggressive measures, it is difficult to halt the progress of HLH and not everyone can undergo SCT. Hence new approaches to salvage such patients are under trials. A combination of Etoposide with anti Thymocyte Globulins looks like an interesting and promising option to improve the outcomes by increasing initial responses and maintaining them until HSCT can be performed in primary/refractory cases. Plasmapheresis to remove excessive cytokines has been performed in few with temporary benefit. Various monoclonal antibodies such as alemtuzumab, infiximab, and daclizumab [43,44] has been described in various case reports with appreciable success rate. Alemtuzumab targets the CD-52 antigen, which is expressed on most lymphocytes, monocytes, macrophages, and dendritic cells. Infiximab and daclizumab targets TNF, CD52 respectively. Rituximab has been used in EBV triggered HLH though with varied success rate. Splenectomy and liver transplant for refractory cases has been proposed with limited success. Being a rare disorder and with lack of data, there is still a long way to develop treatment strategies for refractory and resistant HLH disease. More evidence is required before these can be offered as definitive cure.

**Conclusion**

HLH is a potentially fatal condition is often under diagnosed, missed in children and adults. High index of suspicion in patients presenting with fever, hepatosplenomegaly, pancytopenia, liver dysfunction and coagulopathy is required for diagnosis. Though biochemical markers and tissue diagnostic markers fulfill diagnostic criteria genetic analysis is warranted in all relevant cases as it has specific therapeutic and prognostic implication. Secondary HLH carries good prognosis and at times responds to steroid treatment alone whereas primary/familial HLH can be fatal without SCT after initial phase of therapy. There is a definite paucity of data from India related to HLH and we need studies concentrating on genetic analysis and modified treatment modalities practical to developing countries.

**Acknowledgement**

We acknowledge the writing assistance provided by Dr. Latha MS, Research Consultant, Rainbow children’s hospital, Banjara Hills, Hyderabad, India.

**References**


**Table 4: Initial 8-weeks therapy and maintenance therapy.**

<table>
<thead>
<tr>
<th>No.</th>
<th>Drug</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Etoposide</td>
<td>150 mg/m² intravenous, every second week.</td>
</tr>
<tr>
<td>2.</td>
<td>Dexamethasone</td>
<td>Pulses every 2nd week, 10 mg/m² for 3 days.</td>
</tr>
<tr>
<td>3.</td>
<td>Cyclosporin A</td>
<td>Dose is adjusted to achieve blood levels around 200 mcg/L.</td>
</tr>
</tbody>
</table>

*Not to consider if absolute neutrophil count (ANC) 0.5 × 10⁹/L and the bone marrow is hypocellular.
*Not to consider if absolute neutrophil count (ANC) 0.5 × 10⁹/L and the bone marrow is hypocellular.


